Northland hospices face dire future without funding increase
'We have an ageing population and people live longer and are then more prone to end-of-life illnesses.'
She said they receive about 50% in government funding, and the rest they fundraise.
'That means we have to raise over $4.5 million from the community each year, and in Whangārei we are not a wealthy population so it's not easy.
'This is not sustainable, we won't go past three or four years if we don't get an increase in government funding and that is not an idle threat … We are at risk of disappearing and falling off completely.'
She said they have dipped into their reserves, which was not ideal but was necessary to keep services going.
'It's not fair that the community has to fund at the level that they have to.'
Mid-Northland Hospice chief executive Cristina Ross echoed the sentiments and said they have to raise around $1.5 million each year.
'We have had significant patient growth in Kerikeri alone. Per capita, Kerikeri has a higher concentration of retirement homes and old-age residential care.'
She said while Kerikeri is seen as more well off, there was still a lot of deprivation and people needing their services.
'It's getting really dire. Many hospices are dipping into their reserves just to balance their books, and that is not a sustainable model.'
The acting national director for planning, funding and outcomes at Health NZ Te Whatu Ora, Jason Power, said the agency remains committed to ensuring palliative and end-of-life care, and it is working through increases in funding for hospices.
'We are currently working through uplifts or increases for the funded sector, which includes hospice. Hospices will be advised of the level of uplift, with other contracted providers, when the uplift is confirmed.'
He said that for the 2023/24 financial year, Health NZ provided $113.6 million in funding to 28 hospices.
'We are committed to working with hospices and a range of other services to ensure palliative care meets the needs of all New Zealanders and their families. We regularly engage with hospices and Hospice New Zealand, and they are very much front and centre of our National Palliative Care Work Programme that is under way.'
Hospice NZ chief executive Wayne Naylor said hospices would only see change if more funding was made available.
He said Hospice NZ had given the previous Government and Health NZ information on the impact hospices have.
It had shown them that on top of the care and support hospices give families, hospices save millions of dollars by keeping people out of ERs and hospitals and helping to reduce visits to GPs.
He said each year hospices were having to work harder to raise more money.
'Costs have been escalating a lot over the past five years, and that puts more pressure on communities too.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
an hour ago
- Scoop
Cancer, Measles And Allergic Disease Research Funded In Latest HRC Grants Round
The Malaghan Institute has been awarded three Health Research Council grants, totalling $7.4M over five years, to improve cancer immunotherapies, protect vulnerable populations from measles outbreaks and investigate new therapeutic targets for eczema. Director Professor Kjesten Wiig says receiving three major grants from the Health Research Council at a time of heightened funding constraints is significant and recognises the calibre and relevance of the Malaghan Institute's science. 'These investments not only reflect confidence in the Malaghan's research across cancer, allergic and infectious diseases, but also the real-world impact of our work on the health of New Zealanders.' Faster CARs: Overcoming exhaustion to enhance cancer immunotherapies Building on the Malaghan Institute's ground-breaking CAR T-cell programme, the Perret team in the Weinkove Laboratory has recieved a $1.2 million project grant over three years to improve on this life-saving treatment. 'In Aotearoa's first CAR T-cell trial, our novel CAR T-cell therapy has shown promising safety and efficacy in people with relapsed lymphomas,' says Dr Rachel Perret. 'However, a known limitation of CAR T-cell therapies is that in some cases, cancers fail to respond, or relapse. This may be due to exhaustion of CAR T-cells during manufacture or inside the patient, due to a immunosuppressive environment around the tumour.' Cells, like people, can become exhausted if overworked or overstimulated, becoming less and less able to perform. However, unlike people, CAR T-cells can be tweaked to block the genes that signal this exhaustion, allowing them to continue fighting cancer for longer – which should also improve patient outcomes. 'This project will re-engineer CAR T-cells to silence genes linked to exhaustion and re-develop CAR T-cell manufacturing processes to enhance CAR T- cell fitness and shorten manufacturing times,' says Dr Perret. 'We expect the results to be applicable to many cancer types, and to be readily translated for the benefit of New Zealanders within our CAR T-cell clinical trial programme.' Providing equal protection for everyone against measles Herd immunity is how we as a population protect those who are immunocompromised or otherwise unable to get vaccinated (such as very young infants) against potentially life-threatening viruses like measles. When enough of the population are vaccinated (over 95% in the case of measles), this herd immunity effectively prevents viruses from spreading to our most vulnerable whānau. 'While the current measles, mumps and rubella (MMR) vaccine is highly effective at protecting vaccinated individuals against these viruses, current vaccination rates are not high enough to provide this essential herd immunity to protect those who cannot be vaccinated,' says paediatric immunologist Dr Kuang Hsiao from Waipapa Taumata Rau, University of Auckland, who is part of the research team. The MMR vaccine cannot be used in people with severely impaired immune systems and is not recommended in pregnant people. Also, MMR is less effective in infants, so is not routinely recommended before 12 months of age. In addition, Māori and Pacific communities are overrepresented among these vulnerable groups. For these populations, alternate protective options are required to prevent a measles outbreak. 'Evidence has shown that mRNA-based vaccines can be effective in these vulnerable individuals,' says the Malaghan's Professor Ian Hermans. 'With an international team involving clinicians, immunologists and Māori and Pacific researchers, we will develop an mRNA-based measles vaccine to give to vulnerable individuals in the event of an outbreak.' The research has been awarded an HRC Programme Grant, worth $5M over five years, and will bring together multiple organisations including the Malaghan, representing diverse areas of expertise and combining both fundamental research and public health. 'As part of this work, we will explore with Māori and Pacific communities' perceptions and beliefs about mRNA-based vaccines to support equitable access to the vaccine,' says Dr Hermans. Investigating novel treatment targets for atopic dermatitis Atopic dermatitis, or eczema, is a chronic skin allergic disease that affects a significant proportion of New Zealand's population. The disease can have a significant negative impact on a person's livelihood with symptoms varying from persistent itchiness, redness, dryness and inflammation. Current treatment options are largely immunosuppressants such as corticosteroids, which can cause side effects. While these treatments can help manage symptoms there are currently no effective therapies to prevent the disease from developing and relapsing. At the cellular level, one hallmark of atopic dermatitis is the chronic infiltration and persistence of immune cells called tissue resident memory T-cells. Normally, these cells are vital for protecting the skin from invading pathogens, but for individuals with atopic dermatitis these cells also contribute to the disease by promoting recurring inflammation even after the allergen has been cleared from the skin. The project, which has been awarded $1.2 million over three years, will be led by Dr Sotaro Ochiai, a Senior Research Fellow in the Ronchese Laboratory. The team will focus on better understanding these tissue resident memory T-cells identifying key genes and biological pathways that are essential for the establishment and maintenance of these cells in the skin. 'By understanding these mechanisms, we aim to identify new therapeutic targets to disrupt tissue resident memory T-cell survival or function and improve quality of life for those affected by this persistent and distressing condition,' says Dr Ochiai.
NZ Herald
7 hours ago
- NZ Herald
Tairāwhiti among worst regions for heart failure and care, Health NZ working to improve service
A cardiac catheterisation procedure within three days of arrival at the hospital was performed 28.5% of the time in Tairāwhiti compared to the national average of 64.7%. One positive statistic in the report for Tairāwhiti was that the rate at which first medical contact occurred within 60 minutes of having heart attack symptoms was 80% in Tairāwhiti, compared to a national average of 50.2%. The report drew on Ministry of Health data, which indicated there were no cardiologists in Tairāwhiti. The report also notes the Medical Council Workforce Survey showed Tairāwhiti had 0.4 of a fulltime equivalent cardiologist for the entire region. Overall, the report found the country's heart care system was 'on the verge of collapse'. Māori and Pacific people were hospitalised or died from heart disease more than a decade earlier, on average, than other New Zealanders. The national heart health care system was plagued by chronic under-resourcing, critical workforce shortages and deadly inequities. Heart disease contributed to 5% of hospital admissions and 20% of deaths across the country. Health NZ Tairāwhiti group director of operations, Nicola Barrington, told the Gisborne Herald Health NZ was committed to ensuring patients had timely access to high-quality cardiac services wherever they lived in New Zealand. 'We are working hard to improve heart care services in Tairāwhiti by expanding access to cardiology services through a combination of digital health services, visiting specialists – including locum cardiologists and visiting clinicians – and nurse practitioner support," Barrington said. Health NZ had partnered with HeartLab to reduce wait times for heart scan reporting, she said. Barrington said efforts to recruit cardiology specialists to Tairāwhiti had been ongoing for some time. 'As with many other regions in New Zealand, attracting specialists to rural and regional areas like Tairāwhiti remains a challenge,' she said. 'We are continuing to recruit cardiologists, cardiac care specialists and sonographers to Gisborne Hospital. 'These efforts include a dedicated international recruitment campaign promoting the unique lifestyle and professional opportunities that Tairāwhiti offers. 'Encouragingly, we have received applications from a number of experienced doctors, some of whom we hope will focus their careers on caring for our whānau with cardiac issues in Tairāwhiti.' Barrington said Health New Zealand was funding the training of 26 cardiac sonographers, with 10 graduating by the end of this year and the rest next year. The intention was to place them in the areas of greatest need, 'which includes our region'. Health New Zealand's National Clinical Cardiac Network was developing national standards and models of care, and establishing dedicated work streams, with strong clinical leadership and input from many regions, including Tairāwhiti. 'We are also exploring new ways of working within our region to optimise how we share the cardiology expertise to Tairāwhiti to provide equitable care across Te Manawa Taki [the Tairāwhiti, Waikato, Lakes, Bay of Plenty and Taranaki health districts]'. She said the regional approach meant Tairāwhiti could offer better care and have more options for hiring skilled staff. 'We are planning by looking at ways to make our heart care team more resilient, by continuing to recruit nurse practitioners and specialist nurses. 'Our goal is to build a reliable, patient-focused heart service that meets the needs of people in Tairāwhiti now and in the years ahead,' said Barrington.
Scoop
15 hours ago
- Scoop
New Project Tackles Breast Cancer Inequity
A major new project focused on Māori women with breast cancer is launching, with a $5 million grant from the Health Research Council. University of Auckland Associate Professor George Laking from Te Aka Mātauranga Matepukupuku, Centre for Cancer Research is leading the Whiria te Aka Matua project, with Dr Nina Scott from Te Whatu Ora, Health New Zealand. The five-year project will offer a new model of care designed to overcome inequities faced by Māori women with breast cancer, says Laking. Wāhine Māori have a 46 percent higher incidence of breast cancer than European New Zealanders, he says. When breast cancer is picked up by screening, Māori women have the same chance of survival as other New Zealanders. However, about 45 percent of all wāhine Māori who have breast cancer are diagnosed outside of screening programmes, after they notice symptoms, such as a lump. Māori women with symptomatic breast cancer have a 37 percent lower rate of survival than European New Zealanders, he says. 'The reasons for this are many, but one of the things we urgently need to improve is the design of the health system. 'We hope the model of care we are developing will turn the inequity around, so there's no longer a survival disadvantage for Māori women with symptomatic breast cancer,' says Laking. The research team includes experts from Waipapa Taumata Rau, University of Otago, and Waikato and Auckland hospitals. They aim to enrol 160 Māori women with suspected breast cancer into their study. The women who are diagnosed with breast cancer will receive wrap-around care for themselves and their whānau. Three interventions will be offered, starting with the whiri model of care. This involves a health navigator ensuring the whānau know what is happening, what health services are needed and how to get to appointments. The health navigator will assess the health of the whole family. 'We want to implement a family model of care, in contrast to prevalent models that are centred on individual patients. 'Major health issues have flow-on effects through families. Sometimes one person is diagnosed with cancer and a family member worries themselves sick. 'We want to make sure the health of all people in the family is on track, at a time when they need it,' says Laking. The next intervention will be Whānau Hauora Portfolios. These will provide a core plan of care, which can be easily updated and communicated with different teams. They will also be a place where whānau can record what happens on the cancer journey. The third intervention will be prehabilitation, a holistic programme designed to prepare women for the stress of treatments, such as surgery, radiation and chemotherapy. Prehabilitation - occuring between diagnosis and when treatment begins - could include support with exercise, nutrition, psychological and social needs, and rongoā Māori. 'It will help make sure women are as well as possible at the beginning of their cancer treatment. 'In European populations with cancer, prehabilitation has been shown to shorten the average length of hospital stay and to reduce post-surgical complications,' says Laking. Two evaluations will be offered – the first, assessing signs of inflammation in the women's blood samples, to see how these are affected by prehabiltation and cancer treatments. A holistic evaluation of the value of the entire programme will also be presented. The kete of resources will be co-designed with wāhine Māori with breast cancer, through interviews and focus groups. Several wānanga will be held to collaborate with the wider health community on the programme. Laking says what works for Māori women will have benefits for many patient communities. 'We're focusing our research on Māori women, because that's the area of greatest immediate need, but the model of care we're developing will be useful for all New Zealand women with breast cancer. 'This model could be relevant for a wide range of conditions, not just in Aotearoa, but globally,' says Laking.
